Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (1151-1160 of 1,281) with videos related to

Pageof 129
Sort By:
The Lancet. Oncology|October 19, 2016
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyGlenwood Goss, Chun-Ming Tsai, Frances A Shepherd, et al.
Cancer Medicine|February 13, 2014
Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancersKit Man Wong, Xiaoping Qiu, Dangxiao Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialKaren Kelly, Nasser K Altorki, Wilfried E E Eberhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 studyGlenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.
The New England Journal of Medicine|June 5, 2023
Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.
The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2007
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guidelineKatherine M W Pisters, William K Evans, Christopher G Azzoli, et al.
Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.
Journal of Medicinal Chemistry|October 28, 2005
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in ratsConrad W Hummel, Andrew G Geiser, Henry U Bryant, et al.
Hormones & Cancer|March 12, 2015
Relationship of serum estrogens and metabolites with area and volume mammographic densitiesGretchen L Gierach, Deesha A Patel, Roni T Falk, et al.
Pageof 129

Showing results (1151-1160 of 1,281) with videos related to

Sort By:
Pageof 129
The Lancet. Oncology|October 19, 2016
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyGlenwood Goss, Chun-Ming Tsai, Frances A Shepherd, et al.
Cancer Medicine|February 13, 2014
Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancersKit Man Wong, Xiaoping Qiu, Dangxiao Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialKaren Kelly, Nasser K Altorki, Wilfried E E Eberhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 studyGlenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.
The New England Journal of Medicine|June 5, 2023
Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.
The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2007
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guidelineKatherine M W Pisters, William K Evans, Christopher G Azzoli, et al.
Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.
Journal of Medicinal Chemistry|October 28, 2005
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in ratsConrad W Hummel, Andrew G Geiser, Henry U Bryant, et al.
Hormones & Cancer|March 12, 2015
Relationship of serum estrogens and metabolites with area and volume mammographic densitiesGretchen L Gierach, Deesha A Patel, Roni T Falk, et al.
Pageof 129